AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8383397 — intervention group
Group type: COMPARATOR
Intervention: Captopril (6.25 mg t.i.d. initially, increased to 12.5 mg and 25 mg t.i.d.)
Number of subjects: 0
Study 3048076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Number of subjects: 12
Study 3048076 — intervention group
Group type: EXPERIMENTAL
Intervention: French bread
Number of subjects: 12
Study 3048076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice
Number of subjects: 12
Study 3048076 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 12
Study 29204964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXA)
Number of subjects: 43
Study 29204964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 27340360 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine (10 mg, twice daily)
Number of subjects: 53
Study 27340360 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole (30 mg, once daily)
Number of subjects: 53
Study 26575100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h of cycling at Fatmax (moderate-intensity aerobic exercise)
Number of subjects: 18
Study 26575100 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week lifestyle intervention (dietary calorie restriction and exercise training)
Number of subjects: 18
Study 26575100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h of cycling at Fatmax (moderate-intensity aerobic exercise) after lifestyle intervention
Number of subjects: 18
Study 23554851 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 16
Study 23554851 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 1 mg
Number of subjects: 16
Study 23554851 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 1 mg (active placebo)
Number of subjects: 16
Study 23554851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff algometry
Number of subjects: 16
Study 23554851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pain models
Number of subjects: 16
Study 23554851 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pain models
Number of subjects: 16
Study 20825071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) administered in doses of 0.3 or 0.5 mg into the vitreous body
Number of subjects: 0
Study 20825071 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18223621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (<25% of energy from fat)
Number of subjects: 305
Study 18223621 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fat diet (28-32% of energy from fat)
Number of subjects: 305
Study 18223621 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (>35% of energy from fat)
Number of subjects: 305
Study 16948370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidrion R (SS White)
Number of subjects: 245
Study 16948370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Molar
Number of subjects: 245
Study 12674340 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 7753
Study 12674340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 7753
Study 12674340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrolithiasis
Number of subjects: 7753
Study 12674340 — intervention group
Group type: COMPARATOR
Intervention: Disease conditions
Number of subjects: 7753
Study 10586011 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic prednisolone mixture 2 mg/kg daily for 5 days
Number of subjects: 147
Study 10586011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 8952213 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink driving education program
Number of subjects: 1774
Study 1931705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b) at 1.5 MU/d
Number of subjects: 34
Study 1931705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b) at 1.5 MU three times a week
Number of subjects: 34
Study 1931705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b) at 3.0 MU three times a week
Number of subjects: 34
Study 1931705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b) with reduced doses
Number of subjects: 34
Study 1931705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 34
Study 6277355 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg delta 9THC
Number of subjects: 20
Study 6277355 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg delta 9THC
Number of subjects: 20
Study 6277355 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg delta 9THC
Number of subjects: 20
Study 6277355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6277355 — intervention group
Group type: EXPERIMENTAL
Intervention: delta 9THC
Number of subjects: 20
Study 31186121 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day ibuprofen (600 mg three times a day)
Number of subjects: 95
Study 31186121 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day ibuprofen (600 mg three times a day for 3 days, then placebo for 4 days)
Number of subjects: 95
Study 31186121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 95
Study 27206464 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Mail plus Incentive
Number of subjects: 18939
Study 27206464 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Mail only
Number of subjects: 18939
Study 27206464 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18939
Study 25873553 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (150,000 IU ergocalciferol every 3 months)
Number of subjects: 40
Study 25873553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-awareness assessed with the Beck Cognitive Insight Scale and patient-caregiver discrepancy scores from the Dysexecutive Questionnaire and the Everyday Memory Questionnaire-Revised
Number of subjects: 34
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning measures
Number of subjects: 34
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor complications of PD therapy
Number of subjects: 34
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 34
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication profiles
Number of subjects: 34
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of impulsivity
Number of subjects: 34
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive dysfunction
Number of subjects: 34
Study 23686032 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of inability to resist motivated behaviors
Number of subjects: 34
Study 21075774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1820
Study 19121446 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker alone
Number of subjects: 1269
Study 19121446 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker plus digoxin
Number of subjects: 1269
Study 19121446 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 1269
Study 19121446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta blocker or digoxin)
Number of subjects: 1269
Study 17224434 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling (PC) - wearing a cooling vest (0 degrees C‐5 degrees C) for 20 min at rest
Number of subjects: 20
Study 17224434 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up (WU) - 20 min at 70% maximum heart rate (HR)
Number of subjects: 20
Study 17224434 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - no particular preparation
Number of subjects: 20
Study 17224434 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling (PC)
Number of subjects: 20
Study 17224434 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up (WU)
Number of subjects: 20
Study 15196774 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin-glutamic acid decarboxylase 65 (GAD65)-based enzyme-linked immunosorbent assay (B-ELISA)
Number of subjects: 78
Study 15196774 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 78
Study 11310708 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 72
Study 11310708 — intervention group
Group type: COMPARATOR
Intervention: Levodopa and part‐time occlusion (3 hours/day)
Number of subjects: 72
Study 11310708 — intervention group
Group type: COMPARATOR
Intervention: Levodopa and full‐time occlusion (during all waking hours)
Number of subjects: 72
Study 9135194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms.kg‐1) administered orally 90 min before surgery
Number of subjects: 42
Study 9135194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 42
Study 7835807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening
Number of subjects: 74000
Study 7835807 — intervention group
Group type: EXPERIMENTAL
Intervention: New screening programs for women with a family history of ovarian cancer
Number of subjects: 74000
Study 2405613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (60-90 mg/day)
Number of subjects: 105
Study 2405613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30-90 mg/day)
Number of subjects: 105
Study 2405613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (mean dose 69.4 mg/day)
Number of subjects: 105
Study 2405613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (60 mg/day)
Number of subjects: 105
Study 31688431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bicarbonate on top of hydration
Number of subjects: 0
Study 31688431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bicarbonate on top of hydration
Number of subjects: 0
Study 31688431 — intervention group
Group type: COMPARATOR
Intervention: Hydration alone
Number of subjects: 0
Study 29655859 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training and distress tolerance (mindfulness) interventions
Number of subjects: 0
Study 29655859 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking prevention informational intervention
Number of subjects: 0
Study 26477761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu+Mel+Flu+Ara‐C (BMFA)
Number of subjects: 94
Study 26477761 — intervention group
Group type: COMPARATOR
Intervention: Bu+Cy+Flu+Ara‐C (BCFA)
Number of subjects: 94
Study 24521895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group (n = 24) received solifenacin succinate (5 mg, once a day) and naftopidil (25 mg, every evening)
Number of subjects: 67
Study 24521895 — intervention group
Group type: COMPARATOR
Intervention: Control group I (n = 22) received only solifenacin succinate
Number of subjects: 67
Study 24521895 — intervention group
Group type: COMPARATOR
Intervention: Control group II (n = 21) received only naftopidil
Number of subjects: 67
Study 22041323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg)
Number of subjects: 26
Study 22041323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18081771 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold alloy tip electrodes
Number of subjects: 252
Study 18081771 — intervention group
Group type: COMPARATOR
Intervention: Standard platinum-iridium (Pt-Ir) catheters
Number of subjects: 252
Study 16949486 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice a day (n = 16)
Number of subjects: 33
Study 16949486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 33
Study 14563591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 490
Study 14563591 — intervention group
Group type: COMPARATOR
Intervention: Control (no CRT)
Number of subjects: 490
Study 10823767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inactivated whole cell Vibrio cholerae plus recombinant B subunit cholera vaccine
Number of subjects: 17799
Study 10823767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17799
Study 8857279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration + noise + tool weight
Number of subjects: 0
Study 8857279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration alone
Number of subjects: 0
Study 8857279 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2001053 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP-5
Number of subjects: 10
Study 2001053 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-5
Number of subjects: 10
Study 2001053 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP-0
Number of subjects: 10
Study 2001053 — intervention group
Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 10
Study 6441194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron irradiation
Number of subjects: 0
Study 6441194 — intervention group
Group type: COMPARATOR
Intervention: Mega-voltage X‐rays
Number of subjects: 0
Study 6441194 — intervention group
Group type: EXPERIMENTAL
Intervention: Photons (subgroup treatment for larynx cancer)
Number of subjects: 0
Study 30677636 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted suturing with injected local anaesthetic and Vicryl Rapide 3.0 or equivalent
Number of subjects: 22
Study 30677636 — intervention group
Group type: COMPARATOR
Intervention: Continuous or subcuticular sutures
Number of subjects: 22
Study 30677636 — intervention group
Group type: EXPERIMENTAL
Intervention: Graze (unilateral or bilateral vertical skin separation with minimal trauma)
Number of subjects: 22
Study 29382142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 8
Study 29382142 — intervention group
Group type: COMPARATOR
Intervention: Glucose (G)
Number of subjects: 8
Study 26841341 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine weighing in the antenatal clinic
Number of subjects: 782
Study 26841341 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 782
Study 26841341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 782
Study 25378376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydration
Number of subjects: 225
Study 25378376 — intervention group
Group type: COMPARATOR
Intervention: IV hydration
Number of subjects: 225
Study 25378376 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 225
Study 22702892 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw and 1 cage
Number of subjects: 50
Study 22702892 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screws and 2 cages
Number of subjects: 50
Study 20185972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent psychological intervention
Number of subjects: 52
Study 20185972 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (Control)
Number of subjects: 52
Study 18361754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pickles (PCK) (approximately 1,400 mg of acetic acid daily)
Number of subjects: 27
Study 18361754 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (VIN) (2,800 mg of acetic acid daily)
Number of subjects: 27
Study 18361754 — intervention group
Group type: COMPARATOR
Intervention: Commercial vinegar pills (REF) (30 mg of acetic acid daily)
Number of subjects: 27
Study 15994575 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet (n=75)
Number of subjects: 142
Study 15994575 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=67)
Number of subjects: 142
Study 12766653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with 30 mg of ketorolac
Number of subjects: 10
Study 12766653 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% with normal saline
Number of subjects: 10
Study 9664951 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) - 7 x 4 mg/kg body weight i.v.
Number of subjects: 50
Study 9664951 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP) - 3 x 250 mg i.v.
Number of subjects: 50
Study 9664951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ATG and MP)
Number of subjects: 50
Study 7706148 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching children to ask the question 'What's that?'
Number of subjects: 3
Study 7706148 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of novel information through asking questions
Number of subjects: 3
Study 2785355 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of propofol, 18 mg.kg‐1.h‐1 for the first 30 min and 15 mg.kg‐1.h‐1 thereafter
Number of subjects: 42
Study 2785355 — intervention group
Group type: COMPARATOR
Intervention: 2.5% enflurane, then 2% enflurane after 30 min
Number of subjects: 42
Study 959762 — intervention group
Group type: COMPARATOR
Intervention: Control perfusate
Number of subjects: 11
Study 959762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxy bile acids
Number of subjects: 11
Study 29128650 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month social marketing campaign delivered by child care centers
Number of subjects: 0
Study 29128650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29128650 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month social marketing campaign
Number of subjects: 0
Study 28946866 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powders (MNPs) given daily to caregivers of infants in the treatment group.
Number of subjects: 1802
Study 28946866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MNPs provided).
Number of subjects: 1802
Study 25704725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery arm (a € 1 lottery scratch card sent with the questionnaire)
Number of subjects: 4820
Study 25704725 — intervention group
Group type: COMPARATOR
Intervention: Prize arm (entry into a draw on return of a completed questionnaire)
Number of subjects: 4820
Study 25704725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery arm (long-term survivors)
Number of subjects: 4820
Study 25704725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per completed questionnaire
Number of subjects: 4820
Study 23945720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg Zn/d)
Number of subjects: 42
Study 23945720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20598480 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous treatment with ePTFE/nitinol self-expanding stent graft (n = 50)
Number of subjects: 86
Study 20598480 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment with femoral to above-knee popliteal artery bypass using synthetic conduit (n = 50)
Number of subjects: 86
Study 18067598 — intervention group
Group type: EXPERIMENTAL
Intervention: SLA implants
Number of subjects: 32
Study 18067598 — intervention group
Group type: COMPARATOR
Intervention: TPS implants
Number of subjects: 32
Study 16697124 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg/day)
Number of subjects: 199
Study 16697124 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg/day)
Number of subjects: 199
Study 16697124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amantadine (300 mg/day) and propranolol (100 mg/day)
Number of subjects: 199
Study 16697124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 12743863 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using the photosensitizer SQN 400 and interstitial photodynamic laser treatment
Number of subjects: 5
Study 12743863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of several fibres for tumor ablation
Number of subjects: 5
Study 12743863 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic laser therapy
Number of subjects: 5
Study 11302998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose insulin infusion
Number of subjects: 10
Study 11302998 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose insulin infusion
Number of subjects: 10
Study 11302998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9039246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 micrograms
Number of subjects: 12
Study 9039246 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 500 micrograms
Number of subjects: 12
Study 9039246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1000 micrograms
Number of subjects: 12
Study 9039246 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 1000 micrograms
Number of subjects: 12
Study 9039246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 2000 micrograms
Number of subjects: 12
Study 9039246 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 2000 micrograms
Number of subjects: 12
Study 9039246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7908410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adjuvant chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 442
Study 7908410 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose and low-dose adjuvant chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 442
Study 3265525 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine
Number of subjects: 90
Study 3265525 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline
Number of subjects: 90
Study 3265525 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 90
Study 3265525 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline + 5 mg diazepam
Number of subjects: 90
Study 3265525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90